Fractyl Health, Inc.’s (NASDAQ:GUTS) Lock-Up Period To End on July 31st

Fractyl Health’s (NASDAQ:GUTS) lock-up period is set to end on Wednesday, July 31st. Fractyl Health had issued 7,333,333 shares in its IPO on February 2nd. The total size of the offering was $109,999,995 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Fractyl Health Stock Up 3.7 %

Shares of NASDAQ:GUTS opened at $4.19 on Friday. Fractyl Health has a fifty-two week low of $3.77 and a fifty-two week high of $14.50. The firm’s 50-day simple moving average is $5.38. The company has a quick ratio of 9.37, a current ratio of 9.38 and a debt-to-equity ratio of 0.34.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Monday, May 13th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.45). The business had revenue of $0.03 million during the quarter. As a group, analysts expect that Fractyl Health will post -2.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Fractyl Health stock. American International Group Inc. bought a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,339,261 shares of the company’s stock, valued at approximately $9,911,000. American International Group Inc. owned about 2.80% of Fractyl Health as of its most recent filing with the Securities & Exchange Commission.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.